© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to November
oral reversible BTK kinase inhibitor
Ph. I candidate for multiple sclerosis
from prior BTK inhibitor BIIB0685
Journal of Medicinal Chemistry
5. The Biogen reversible BTK kinase inhibitor, BIIB091, is a highly selective, phase I clinical candidate for multiple sclerosis. Irreversible BTK inhibitors have been explored and developed extensively, primarily in…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.